Sandbox:ap: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Matt Pijoan (talk | contribs) No edit summary |
||
Line 15: | Line 15: | ||
{{familytree/end}} | {{familytree/end}} | ||
== Differential diagnosis == | == [[Differential Cyanosis|Differential]] diagnosis == | ||
{| | {| | ||
! colspan="4" style="background: #4479BA; text-align: center;" |{{fontcolor|#FFF|Hypoparathyroidism}} | ! colspan="4" style="background: #4479BA; text-align: center;" |{{fontcolor|#FFF|Hypoparathyroidism}} | ||
Line 22: | Line 22: | ||
! style="background: #4479BA; text-align: center;" |{{fontcolor|#FFF|Clinical features}} | ! style="background: #4479BA; text-align: center;" |{{fontcolor|#FFF|Clinical features}} | ||
|- | |- | ||
| colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" | | | colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Autoimmune | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" | | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |Autoimmune polyglandular hypoparathyroidism | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" | | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |Autoimmune polyglandular endocrinopathy type 1 | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Autosomal recessive]] | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Autosomal recessive]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Mutation in AIRE gene | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Mutation in AIRE gene | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Also known as | *Also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). | ||
*Presents with a variable combination of: | *Presents with a variable combination of: | ||
**Failure of the | **Failure of the parathyroid glands, adrenal cortex, gonads, pancreatic beta cells, gastric parietal cells, and thyroid gland, and hepatitis | ||
**Chronic | **Chronic mucocutaneous candidiasis | ||
** | **Dystrophy of dental enamel and nails, alopecia, vitiligo, and keratopath | ||
|- | |- | ||
| colspan="2" rowspan="7" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Isolated | | colspan="2" rowspan="7" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Isolated | ||
Line 39: | Line 39: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |PTH gene | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |PTH gene | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Clinical features of hypocalcemia including | *Clinical features of hypocalcemia including | ||
** | **Tetany (hallmark of acute hypocalcemia) | ||
** | **Paresthesia in fingertips, toes, perioral area | ||
** | **Carpopedal spasms | ||
**Circumoral | **Circumoral numbness | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[GCM2]] gene | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[GCM2]] gene | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Clinical features of hypocalcemia including | *Clinical features of hypocalcemia including | ||
** | **Tetany (hallmark of acute hypocalcemia) | ||
** | **Paresthesia in fingertips, toes, perioral area | ||
** | **Carpopedal spasms | ||
**Circumoral | **Circumoral numbness | ||
*[[Dominant negative mutation]] | *[[Dominant negative mutation]] | ||
|- | |- | ||
| rowspan="2" style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Autosomal recessive]] | | rowspan="2" style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Autosomal recessive]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |PTH gene | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |PTH gene | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Clinical features of hypocalcemia including | *Clinical features of hypocalcemia including | ||
** | **Tetany (hallmark of acute hypocalcemia) | ||
** | **Paresthesia in fingertips, toes, perioral area | ||
** | **Carpopedal spasms | ||
**Circumoral | **Circumoral numbness | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[GCM2]] gene<ref name="pmid18712808" /> | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Clinical features of hypocalcemia including | *Clinical features of hypocalcemia including | ||
** | **Tetany (hallmark of acute hypocalcemia) | ||
** | **Paresthesia in fingertips, toes, perioral area | ||
** | **Carpopedal spasms | ||
**Circumoral | **Circumoral numbness | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[X-linked]] | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[X-linked]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[FHL1 (gene)|FHL1]] gene (exon 4, c.C283T, p.R95W) on chromosome locus Xq26-q27. | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[FHL1 (gene)|FHL1]] gene (exon 4, c.C283T, p.R95W) on chromosome locus Xq26-q27. | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Clinical features of hypocalcemia including | *Clinical features of hypocalcemia including | ||
** | **Tetany (hallmark of acute hypocalcemia) | ||
** | **Paresthesia in fingertips, toes, perioral area | ||
** | **Carpopedal spasms | ||
**Circumoral | **Circumoral numbness | ||
|- | |- | ||
| rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Autosomal dominant hypercalcemia | | rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Autosomal dominant hypercalcemia | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |Autosomal dominant hypocalcemia type 1 | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |Autosomal dominant hypocalcemia type 1 | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Autosomal dominant]] | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Autosomal dominant]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Calcium-sensing receptor gene mutation | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*[[Calcium-sensing receptor]] gene activating mutation. | *[[Calcium-sensing receptor|Calcium-sensing]] receptor gene activating mutation. | ||
*'''Most common genetic form''' of hypoparathyroidism. | *'''Most common genetic form''' of hypoparathyroidism. | ||
*Also known as familial hypercalciuric hypocalcemia. | *Also known as familial hypercalciuric hypocalcemia. | ||
*The activating mutation results in gain in function. | *The activating mutation results in gain in function. | ||
* | *Calcium-sensing receptor gene activating mutation can also cause Bartter syndrome type 5.This mutation cause the inhibition of apical potassium channel in the thick ascending limb of the loop of Henle in the kidney. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |Autosomal dominant hypocalcemia type 2 | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |Autosomal dominant hypocalcemia type 2 | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Autosomal dominant]] | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Autosomal dominant]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |G protein G11 ( | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |G protein G11 (GNA11) mutation | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Clinical features of hypocalcemia including | *Clinical features of hypocalcemia including | ||
** | **Tetany (hallmark of acute hypocalcemia) | ||
** | **Paresthesia in fingertips, toes, perioral area | ||
** | **Carpopedal spasms | ||
**Circumoral | **Circumoral numbness | ||
|- | |- | ||
| colspan="2" rowspan="6" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Congenital multisystem syndromes | | colspan="2" rowspan="6" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Congenital multisystem syndromes | ||
Line 120: | Line 120: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Deletion of the [[TBCE]] gene | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Deletion of the [[TBCE]] gene | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Presents with [[hypoparathyroidism]] due to absent | * Presents with [[hypoparathyroidism]] due to absent parathyroid tissue, growth retardation, medullary stenosis of tubular bones. | ||
|- | |- | ||
| colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |'''Kenny-Caffey syndrome type 2''' | | colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |'''Kenny-Caffey syndrome type 2''' | ||
Line 126: | Line 126: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Mutation of “family with sequence similarity 111, member A″ (FAM111A) gene located on chromosome locus 11q12.1 | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Mutation of “family with sequence similarity 111, member A″ (FAM111A) gene located on chromosome locus 11q12.1 | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Patients with Kenny-Caffey sundrome type 2 have same clinical features as Kenny-Caffey syndrome type 1 except for | * Patients with Kenny-Caffey sundrome type 2 have same clinical features as Kenny-Caffey syndrome type 1 except for mental retardation. | ||
|- | |- | ||
| colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |'''Sanjad-Sakati syndrome''' | | colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |'''Sanjad-Sakati syndrome''' | ||
Line 139: | Line 139: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Mutation|Mutations]] in the [[GATA3]] gene | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Mutation|Mutations]] in the [[GATA3]] gene | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Also known as hypoparathyroidism, [[deafness]], and renal dysplasia (HDR) syndrome | *Also known as hypoparathyroidism, [[deafness]], and renal dysplasia (HDR) syndrome | ||
*Presents with primary hypoparathyroidism, nerve [[deafness]], steroid-resistant [[nephrosis]]. | *Presents with primary hypoparathyroidism, nerve [[deafness]], steroid-resistant [[nephrosis]]. | ||
|- | |- | ||
Line 148: | Line 148: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | mtDNA deletion | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | mtDNA deletion | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Progressive external | *Progressive external ophthalmoplegia | ||
* | *Retinitis pigmentosa | ||
* | *Cardiomyopathy | ||
* | *Heart block | ||
|- | |- | ||
| colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Maternally inherited diabetes and deafness (MIDD) | | colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Maternally inherited diabetes and deafness (MIDD) | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | Mitochondrial inheritence | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | Mitochondrial inheritence | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | MT‑TL1 | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | MT‑TL1 | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* | *Diabetes mellitus and deafness | ||
|- | |- | ||
| rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Mitochondrial enzyme deficiencies | | rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Mitochondrial enzyme deficiencies | ||
Line 165: | Line 164: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | HADHA or HADHB gene mutation | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | HADHA or HADHB gene mutation | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Clinical features of mitochondrial trifunctional protein deficiency occurring | *Clinical features of mitochondrial trifunctional protein deficiency occurring during infancy include: | ||
** | **Feeding difficulties | ||
** | **Lethargy | ||
** | **Hypoglycemia | ||
** | **Hypotonia | ||
** | **Liver problems | ||
* | *Infants with mitochondrial trifunctional protein deficiency are also at increased risk for: | ||
**Serious | **Serious heart problems | ||
** | **Breathing difficulties | ||
** | **Coma | ||
** | **Sudden death | ||
*Clinical features of mitochondrial trifunctional protein deficiency occurring | *Clinical features of mitochondrial trifunctional protein deficiency occurring after infancy include: | ||
** | **Hypotonia | ||
** | **Muscle pain | ||
**Breakdown of muscle tissue | **Breakdown of muscle tissue | ||
** | **Peripheral neuropathy | ||
|- | |- | ||
| colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" | | | colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency (LCHAD deficiency) | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Autosomal recessive]] | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Autosomal recessive]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |G1528C gene mutation | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |G1528C gene mutation | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Clinical features of | *Clinical features of LCHAD deficiency include: | ||
** | **Hypoglycemia | ||
** | **Hepatopathy | ||
** | **Hypotonia | ||
** | **Cardiomyopathy | ||
** | **Retinopathy | ||
|- | |- | ||
| rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Heavy metal storage disorders | | rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Heavy metal storage disorders | ||
| colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Hemochromatosis | | colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Hemochromatosis | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Autosomal recessive]] | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Autosomal recessive]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |HFE gene mutation | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Early symptoms of | *Early symptoms of hereditary hemochromatosis are nonspecific and may include: | ||
** | **Fatigue | ||
** | **Joint pain | ||
** | **Abdominal pain | ||
** | **Decreased libido | ||
*Late stage clinical features may include: | *Late stage clinical features may include: | ||
** | **Arthritis | ||
** | **Liver disease | ||
** | **Diabetes | ||
** | **Heart abnormalities | ||
** | **Skin discoloration. | ||
|- | |- | ||
| colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Wilson's disease | | colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Wilson's disease | ||
Line 214: | Line 213: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ATP7B gene mutation | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ATP7B gene mutation | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Clinical features of | *Clinical features of Wilson's disease include: | ||
** | **Initial feature | ||
*** | ***Children and young adults: Liver disease | ||
*** | ***Adults: nervous system disorders and psychiatric problems | ||
*Other clinical features include: | *Other clinical features include: | ||
** | **Clumsiness | ||
** | **Tremors | ||
** | **Difficulty walking | ||
** | **Speech problems | ||
**Impaired thinking ability | **Impaired thinking ability | ||
** | **Depression | ||
** | **Anxiety | ||
** | **Mood swings. | ||
|} | |} | ||
<references /> | <references /> |
Revision as of 17:07, 3 October 2017
Hypercalcemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Related to Parathyroid gland | Unrelated to parathyroid gland | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Primary hyperparathyroidism | Secondary hyperparathyroidism | Tertiary hyperparathyroidism | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Typical primary hyperparathyroidism | Familial hypocalciuric hypercalcemia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Malignancy | Medication induced | Nutritional | Granulomatous disease | Surgical | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Para-neoplastic syndrome: Parathyroid hormone related peptide | Metaplasia: Hypercalcemia due to bone destruction | Thiazide diuretics | Lithium | Milk alkali syndrome | Vitamin D toxicity | Sarcoidosis | Immobilization | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Differential diagnosis
Hypoparathyroidism | Inheritance | Gene mutation | Clinical features | |||
---|---|---|---|---|---|---|
Autoimmune | Autoimmune polyglandular hypoparathyroidism | Autoimmune polyglandular endocrinopathy type 1 | Autosomal recessive | Mutation in AIRE gene |
| |
Isolated | Familial Isolated hypoparathyroidism | Autosomal dominant | PTH gene |
| ||
GCM2 gene |
| |||||
Autosomal recessive | PTH gene |
| ||||
GCM2 gene[1] |
| |||||
X-linked | FHL1 gene (exon 4, c.C283T, p.R95W) on chromosome locus Xq26-q27. |
| ||||
Autosomal dominant hypercalcemia | Autosomal dominant hypocalcemia type 1 | Autosomal dominant | Calcium-sensing receptor gene mutation |
| ||
Autosomal dominant hypocalcemia type 2 | Autosomal dominant | G protein G11 (GNA11) mutation |
| |||
Congenital multisystem syndromes | DiGeorge syndrome | Autosomal dominant | 22q11.2 deletion. |
| ||
CHARGE syndrome | Autosomal dominant | CHD7 G744S missense mutation |
| |||
Kenny-Caffey syndrome type 1 | Autosomal recessive | Deletion of the TBCE gene |
| |||
Kenny-Caffey syndrome type 2 | Autosomal dominant | Mutation of “family with sequence similarity 111, member A″ (FAM111A) gene located on chromosome locus 11q12.1 |
| |||
Sanjad-Sakati syndrome | Autosomal recessive | Mutation in TBCE gene. |
| |||
Barakat syndrome | Autosomal recessive | Mutations in the GATA3 gene | ||||
Metabolic diseases | Mitochondiral polyneuropathies | Kearns–Sayre syndrome | Mitochondrial inheritence | mtDNA deletion |
| |
Maternally inherited diabetes and deafness (MIDD) | Mitochondrial inheritence | MT‑TL1 |
| |||
Mitochondrial enzyme deficiencies | Mitochondrial trifunctional protein deficiency (MTP deficiency) | Autosomal recessive | HADHA or HADHB gene mutation |
| ||
Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency (LCHAD deficiency) | Autosomal recessive | G1528C gene mutation |
| |||
Heavy metal storage disorders | Hemochromatosis | Autosomal recessive | HFE gene mutation |
| ||
Wilson's disease | Autosomal recessive | ATP7B gene mutation |
|
- ↑ Invalid
<ref>
tag; no text was provided for refs namedpmid18712808